Hikal Limited has announced the record date for its interim dividend payment for the financial year 2025-26. The pharmaceutical and specialty chemicals company has set February 17, 2026 as the cut-off date for determining shareholder eligibility for the dividend distribution.

Board Approval and Regulatory Compliance

The company's Board of Directors approved the interim dividend at their meeting held on February 11, 2026. Hikal has formally communicated this decision to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Record Date Details

The key details of the dividend announcement are as follows:

Shareholder Eligibility

Shareholders who hold equity shares of Hikal Limited as of the close of business on February 17, 2026 will be eligible to receive the interim dividend for the financial year 2025-26. The record date serves as the cut-off for determining which investors are entitled to the dividend payment.

Corporate Communication

The official intimation was signed by Rajasekhar Reddy, Company Secretary and Compliance Officer of Hikal Limited, on February 11, 2026. The company has also notified relevant depositories including Central Depository Services (India) Limited and National Securities Depository Limited, along with the registrar and transfer agent MUFG Intime India Private Limited.

This dividend declaration reflects the company's commitment to returning value to shareholders during the ongoing financial year. The record date announcement provides shareholders with clear timeline information for dividend eligibility.

Hikal Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, reporting a net loss amid challenging market conditions. The company has now officially confirmed the record date for interim dividend payment following regulatory compliance requirements.

Financial Performance Overview

The company reported mixed financial performance with revenue growth but profitability challenges during the quarter.

For the nine months period, the company faced revenue decline with total revenue from operations at ₹11,932 million compared to ₹13,074 million in the previous year, representing a decrease of 8.7%.

Segment-wise Performance

Both business segments showed mixed results during the quarter:

The pharmaceuticals segment showed stronger growth momentum despite facing regulatory challenges, while the crop protection segment maintained steady performance.

Official Record Date Confirmation

Following the board meeting held on February 11, 2026, Hikal Limited has formally communicated the record date details to stock exchanges under Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has notified Central Depository Services (India) Limited, National Securities Depository Limited, and registrar MUFG Intime India Private Limited regarding the record date fixation.

Dividend Declaration Details

The Board of Directors had earlier declared an interim dividend for shareholders:

Regulatory Compliance and Trading Window

The formal intimation was signed by Company Secretary & Compliance Officer Rajasekhar Reddy, ensuring compliance with regulatory requirements. The trading window for designated persons will reopen on February 14, 2026, following the closure since January 1, 2026.